MRD Targets — What They Are and Why They Matter
MRD Targets — What They Are and Why They Matter
What is MRD?
Measurable Residual Disease (MRD) refers to the small number of leukemia cells that may remain after treatment, even when standard assessments (blood counts, bone marrow morphology) suggest remission. MRD testing uses highly sensitive molecular methods (NGS, PCR, or multiparameter flow cytometry) to detect residual leukemia at levels of 1 in 10,000 to 1 in 1,000,000 cells — far below what a microscope can see.
What is an MRD Target?
An MRD target is a specific molecular marker — typically a gene mutation unique to the patient's leukemia — that is tracked over time to determine whether residual disease persists. The ideal MRD target is:
- Leukemia-specific — present in the leukemic clone but not in normal cells or age-related clonal hematopoiesis (CHIP)
- Stable — does not spontaneously appear or disappear between timepoints
- Quantifiable — can be measured as a variant allele frequency (VAF) to track the depth of response
Why MRD Matters
- Deeper response assessment: Morphologic complete remission (CR, <5% blasts) is a crude measure. Many patients in morphologic CR still harbor measurable disease that predicts relapse.
- Prognosis: MRD-negative status is associated with significantly longer remission and overall survival. MRD-positive patients have 2–4x higher relapse risk.
- Treatment decisions: MRD results can guide whether to intensify therapy, proceed to allogeneic HSCT, or continue/discontinue maintenance therapy.
- Early relapse detection: Rising MRD levels can signal impending relapse before it becomes clinically apparent, potentially enabling preemptive intervention.
Ishamma's MRD Landscape
Per the Oncomine NGS panel (Aml), six mutations were identified at diagnosis. Their suitability as MRD targets varies:
| Mutation | VAF at Dx | MRD Target? | Rationale |
|---|---|---|---|
| RUNX1 p.(Asp93GlyfsTer32) | 4% | Preferred — primary | Frameshift truncation. Leukemia-specific (not typical CHIP mutation). Recommended by Agilus molecular report as the preferred MRD marker. |
| ASXL1 p.(Trp1411Ter) | 28% | Not as sole target | Very common in CHIP, especially in elderly. Can persist even after leukemia clearance → false-positive MRD. |
| BCOR p.(Arg810Ter) | 17% | Supplementary | May represent founding clone. Low-VAF persistence could reflect residual clonal hematopoiesis rather than active leukemia. |
| SRSF2 p.(Pro95His) | 31% | Not as sole target | Canonical CHIP mutation (Pro95His hotspot). High frequency in age-related clonal hematopoiesis makes it unreliable for MRD. |
| STAG2 p.(Met1102TyrfsTer34) | 16% | Supplementary | Less CHIP-associated than ASXL1/SRSF2. Can support composite MRD assessment. |
| NRAS p.(Gly12Asp) | 3% | No | Subclonal and unstable — can appear/disappear independent of treatment response. Not reliable for longitudinal tracking. |
Recommended approach: Composite MRD panel with RUNX1 as primary marker, BCOR and STAG2 as supporting markers. Clearance of all three = high-confidence MRD negativity.
CHIP Caveat
CHIP (Clonal Hematopoiesis of Indeterminate Potential) mutations — especially ASXL1 and SRSF2 — are common in patients >70 years old and can persist even after successful leukemia treatment. Using these as sole MRD markers would overestimate residual disease. This is why RUNX1, which is leukemia-specific rather than CHIP-associated, is the preferred target.
Current MRD Status
The Day 21 bone marrow biopsy (Bone Marrow Biopsy 2025 12 31) assessed morphologic response (cellularity 60% → 25–30%, reticulin improvement). No NGS-based MRD assessment is documented in the ingested raw files.
Gap: It would be appropriate to discuss with Bijay Prabhakaran Nair whether molecular MRD assessment (NGS tracking RUNX1 VAF) is planned — typically performed after 2–3 cycles of therapy to guide treatment intensity and duration decisions.
Why Track RUNX1 MRD When Transplant Is Not an Option?
At age 81, allogeneic HSCT is not feasible for Ishamma. However, MRD monitoring with RUNX1 remains clinically valuable for several non-transplant reasons:
1. Guiding Treatment Duration and Intensity
Aza-Ven in elderly/unfit AML is continued indefinitely until progression or intolerable toxicity. MRD results inform:
- MRD-negative: Supports staying the course; may justify dose reduction or cycle spacing to reduce cumulative toxicity and improve quality of life
- MRD-positive but stable: Supports continuing current regimen without escalation
- MRD rising: Early warning of relapse — potentially prompting a regimen change before overt relapse, when options are better
2. Early Relapse Detection
RUNX1 VAF can start rising weeks to months before blast counts increase on CBC or morphology. This lead time could allow switching to a salvage regimen, adjusting venetoclax duration/dose, or considering clinical trials while the patient is still in good performance status.
3. Confirming Depth of Response
The Day 21 BMBx (Bone Marrow Biopsy 2025 12 31) showed morphologic response (cellularity 60% → 25–30%), but morphology alone cannot determine whether the leukemic clone is actually shrinking at a molecular level. RUNX1 VAF dropping from the diagnostic 4% toward undetectable would confirm deep molecular response — a more meaningful milestone.
4. Distinguishing True Response from CHIP Persistence
At age 81, CHIP mutations (ASXL1 at 28% VAF, SRSF2 at 31% VAF) may persist even after successful leukemia treatment — they likely represent pre-existing clonal hematopoiesis from which the leukemia evolved. RUNX1, being leukemia-specific, gives a clean signal: clearance = leukemia responding; persistence = active disease remains.
Bottom Line
Transplant is only one of several treatment decisions MRD informs. For a non-transplant patient on indefinite Aza-Ven, MRD monitoring with RUNX1 serves as a molecular compass — confirming response, detecting early relapse, and guiding how long and how aggressively to treat.
Related Pages
- Aml — Underlying diagnosis and full molecular profile
- Bone Marrow Biopsy 2025 12 31 — Day 21 morphologic response assessment
- Azacitidine / Venetoclax — Current treatment regimen
- Bijay Prabhakaran Nair — Treating oncologist
Filed from query, 2026-04-17.